Anti‐PD1/PD‐L1 antibody plus HER2 antibody and chemotherapy have become the new first‐line therapy for HER2 overexpression‐positive advanced GC, suggesting that HER2 and PD‐L1 play a significant role in guiding personalized treatment for patients with GC. Here, ERBB2 is linked to gastric cancer.